STOCK TITAN

Medtronic - MDT STOCK NEWS

Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.

Overview

Medtronic (MDT) is a global healthcare technology company renowned for its development and manufacture of innovative therapeutic medical devices. Operating across a broad spectrum of chronic and acute medical conditions, Medtronic delivers solutions that range from cardiac care to neuromodulation, spinal treatments, and diabetes management. Leveraging advanced technology in areas such as robotics, imaging, and artificial intelligence, the company is central in addressing some of the most challenging health problems of our time.

Core Business and Products

Medtronic’s operations are built on decades of experience in designing, manufacturing, and marketing a diverse portfolio of medical devices. Their offering includes therapeutic devices such as pacemakers, defibrillators, heart valves, and stents, as well as advanced surgical tools, spinal fixation devices, neurovascular products, and insulin pumps. Each product category is developed through a rigorous process that emphasizes quality, patient safety, and robust clinical evidence. The company’s products are engineered to meet the demanding needs of healthcare institutions and professionals in both domestic and international markets.

Technological Innovation

At the core of Medtronic’s success is its commitment to technological innovation. The company integrates advanced systems in medical robotics, data analytics, and state-of-the-art imaging to enhance procedural accuracy. For instance, its ecosystem that connects navigation, robotics, and data analytics exemplifies how integrated solutions can lead to more predictable outcomes in complex procedures. Medtronic has also embraced adaptive technology in neuromodulation, shown by its work in adaptive deep brain stimulation, which personalizes therapy based on real-time neural signals.

Global Market Position and Operational Excellence

Medtronic operates with a global mindset, reaching patients in more than 150 countries. With its operational headquarters in the United States and legal headquarters in Ireland, the company effectively navigates diverse regulatory landscapes to maintain compliance while delivering high-quality medical devices. Approximately half of its revenue comes from international markets, underscoring its significance as a major player in the global medtech industry.

Partnerships and Industry Collaborations

Strategic partnerships further strengthen Medtronic’s market position. Collaborations with leading companies, such as those in imaging technology, enhance its product capabilities and help integrate novel hardware, software, and data-driven insights into clinical practice. These collaborations not only improve procedural outcomes but also provide a competitive edge in a field that continuously demands innovative therapeutic solutions.

Commitment to Quality and Clinical Expertise

Medtronic’s approach is deeply rooted in a commitment to clinical excellence and rigorous research. Every device is developed in accordance with strict quality controls and regulatory standards to ensure patient safety and efficacy. This clinical rigor, combined with an insatiable curiosity and diverse expertise, defines the company’s continued success. It is this commitment that has enabled Medtronic to remain at the forefront of treating over 70 critical health conditions through a continuously evolving product pipeline.

Industry Impact and Relevance

For investors and healthcare professionals, Medtronic represents more than just a manufacturer of medical devices. It embodies the transformative power of innovation in medicine by consistently addressing unmet clinical needs and improving patient outcomes. The company’s comprehensive portfolio and its integration of breakthrough technologies have set a benchmark for safety, reliability, and clinical performance in the competitive medical technology landscape.

Summary

In summary, Medtronic’s strength lies in its global scale, technological prowess, and ability to integrate complex therapeutic solutions seamlessly into clinical workflows. Its dedication to alleviating pain, restoring health, and extending life makes it a foundational pillar in modern healthcare, continuously evolving to meet the dynamic needs of patients and physicians alike.

Rhea-AI Summary

Medtronic plc (NYSE:MDT), the global healthcare technology leader based in Galway, Ireland, has announced its participation in the 43rd annual J.P. Morgan healthcare conference on Monday, January 13, 2025. Geoff Martha, chairman and CEO, will deliver a formal presentation and participate in a Q&A session starting at 2:15 p.m. PST.

The presentation and Q&A session will be accessible via live webcast through Medtronic's investor relations website, with an archived version available later that day. Medtronic employs over 95,000 passionate professionals across more than 150 countries, focusing on treating 70 health conditions through various technologies including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems. The company's mission centers on alleviating pain, restoring health, and extending life, helping two people every second globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
conferences
-
Rhea-AI Summary

Medtronic (NYSE: MDT) has declared a quarterly cash dividend of $0.70 per ordinary share for the third quarter of fiscal year 2025. The dividend will be payable on January 10, 2025, to shareholders of record as of December 27, 2024. This declaration aligns with the dividend increase announced in May 2024.

As a member of the S&P 500 Dividend Aristocrats index, Medtronic has maintained a 47-year streak of consecutive annual dividend increases. The company operates globally with 95,000+ employees across 150+ countries, focusing on healthcare technology solutions that address 70 different health conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
dividends earnings
-
Rhea-AI Summary

Medtronic addresses the environmental impact of healthcare technology, highlighting that the healthcare sector contributes to 4.6% of global greenhouse gas emissions. The company emphasizes three key approaches to sustainable healthcare: recognizing development timelines, reimagining products and packaging, and recruiting partners. Medtronic has installed 22 solar arrays across 16 locations, generating over 35 MWs of power, and signed a virtual power purchase agreement to cover nearly all U.S. energy needs. The company is focusing on sustainable product design through its Sustainability Development Center and emphasizes the importance of supply chain collaboration, as Scope 3 emissions account for over 90% of their carbon footprint.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
none
Rhea-AI Summary

Medtronic has released its fiscal year 2024 Impact Report, highlighting achievements in healthcare equity and environmental sustainability. The report features the success of the Healthy Neighbor program, showing 71% of enrolled patients with high blood pressure and 63% with uncontrolled diabetes achieved meaningful progress. The company reached 51% women in its global workforce and reduced emissions intensity by 52% compared to FY20. Key accomplishments include investing $2.7 billion in R&D, improving healthcare access for over 78 million patients, and meeting 42% of operational energy needs with renewables. The company is on track for several sustainability goals, including sourcing 50% of energy from renewable sources by FY25.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
-
Rhea-AI Summary

Medtronic (NYSE: MDT) has received FDA clearance for its new InPen™ app with missed meal dose detection, enabling the launch of its Smart MDI system with Simplera™ CGM. The system combines a smart insulin pen with a new disposable CGM that's 50% smaller than previous versions. This marks the first system to provide real-time, personalized recommendations for missed or inaccurate insulin doses. The technology addresses a critical need, as patients typically miss 1 in 3 insulin doses. The company plans a phased rollout, starting with existing CGM and InPen™ customers before a broader commercial launch.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
-
Rhea-AI Summary

Medtronic (MDT) reported strong Q2 FY25 results with revenue of $8.4 billion, up 5.3% as reported and 5.0% organic. GAAP EPS was $0.99, while non-GAAP EPS reached $1.26. The company raised its FY25 guidance, now expecting organic revenue growth of 4.75-5% and non-GAAP EPS of $5.44-$5.50.

Growth was driven by innovation across key franchises including TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation. The Cardiovascular portfolio grew 6.1%, Neuroscience increased 7.1%, Medical Surgical rose 1.2%, and Diabetes jumped 12.4%. Strong performance in international markets and continued adoption of new products contributed to the positive results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
Rhea-AI Summary

Medtronic (NYSE:MDT) has announced it will release its second quarter fiscal year 2025 financial results on Tuesday, November 19, 2024, at approximately 5:45 a.m. CST. The company will host a video webcast at 7:00 a.m. CST to discuss the results. The fiscal quarter ended on October 25, 2024. Future earnings releases are scheduled for February 18, 2025 (Q3) and May 21, 2025 (Q4). Medtronic, headquartered in Galway, Ireland, operates across 150+ countries with 95,000+ employees, providing technologies and therapies that treat 70 health conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
-
Rhea-AI Summary

Medtronic (NYSE: MDT) announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for its Symplicity Spyral™ renal denervation catheter, effective January 1, 2025, for up to three years. The TPT approval aims to improve patient access to this breakthrough treatment for uncontrolled high blood pressure by reducing cost barriers for healthcare systems. The device, FDA-approved in November 2023, is a minimally invasive procedure that uses radiofrequency energy to calm overactive kidney nerves contributing to high blood pressure. The system is currently approved in over 75 countries and has been used to treat more than 25,000 patients globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
Rhea-AI Summary

Medtronic (NYSE: MDT) announced new two-year data from its SPYRAL HTN-ON MED clinical trial showing significant blood pressure reductions using the Symplicity™ Spyral renal denervation (RDN) system. The study demonstrated superior results compared to sham patients, with RDN group showing -12.1 mmHg reduction in 24-hr ABPM versus -7.0 mmHg in sham group. The company also announced plans for the SPYRAL GEMINI clinical trial to study multi-organ denervation, and the expansion of the GSR-DEFINE clinical trial to U.S. sites. The Symplicity Spyral system is currently approved in over 75 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
none
Rhea-AI Summary

Medtronic (NYSE: MDT) has received FDA approval for its Affera™ Mapping and Ablation System with Sphere-9™ Catheter, making it the first company with two pulsed field ablation (PFA) technologies for atrial fibrillation treatment. The system combines high-density mapping with dual energy (pulsed field and radiofrequency) ablation capabilities for treating persistent atrial fibrillation and atrial flutter. The Sphere-9 catheter features a 9mm lattice tip and enables physician treatment flexibility with its wide area focal design. The approval follows successful results from the SPHERE Per-AF study and previous CE Mark and Australian approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags

FAQ

What is the current stock price of Medtronic (MDT)?

The current stock price of Medtronic (MDT) is $88.49 as of April 1, 2025.

What is the market cap of Medtronic (MDT)?

The market cap of Medtronic (MDT) is approximately 113.8B.

What is the core business of Medtronic?

Medtronic develops and manufactures therapeutic medical devices for chronic diseases, including cardiac devices, neuromodulation, spinal therapies, and diabetes management tools.

How does Medtronic generate revenue?

The company generates revenue through the direct sale of its innovative medical devices and systems to healthcare institutions and professionals across the globe.

What markets does Medtronic serve?

Medtronic serves a global market, with significant operations in the United States, Europe, and other international markets, reaching patients in over 150 countries.

How does Medtronic maintain its competitive edge?

Medtronic maintains its competitive advantage through continuous technological innovation, strategic partnerships, and a commitment to clinical excellence and regulatory compliance.

What role do partnerships play in Medtronic's strategy?

Strategic partnerships, such as those with leading imaging and technology companies, enable Medtronic to integrate advanced features into its devices, thereby enhancing clinical outcomes and broadening its market reach.

How is Medtronic positioned in the medical technology industry?

Medtronic is a key player in the medtech industry, known for its comprehensive product portfolio, innovative technological solutions, and strong global market presence, addressing over 70 health conditions.

What types of products does Medtronic offer?

Medtronic offers a wide range of products including cardiac devices, spinal fixation systems, neurovascular products, insulin pumps, surgical tools, and advanced neuromodulation devices.

What distinguishes Medtronic's approach to innovation?

The company emphasizes rigorous clinical research, quality assurance, and the integration of cutting-edge technologies such as robotics and adaptive deep brain stimulation to deliver patient-centric solutions.

How does Medtronic address patient safety?

Medtronic adheres to strict quality controls and regulatory standards to ensure its devices are safe and effective, placing a high priority on patient outcomes and clinical performance.

What is Medtronic's global impact on healthcare?

By delivering innovative medical solutions and continuously evolving its product pipeline, Medtronic plays a critical role in transforming healthcare globally, positively impacting millions of patients every day.
Medtronic

NYSE:MDT

MDT Rankings

MDT Stock Data

113.81B
1.28B
0.26%
86.22%
1.05%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
Ireland
GALWAY